R289 continues to be generally well tolerated and at doses of ≥500 mg QD preliminary efficacy was observed in elderly, heavily pre-treated lower-risk MDS patients RBC-TI was achieved by 33%...

Emerging tests and treatment strategies guide more tailored approaches and ease the burden on patients ORLANDO, Fla., Dec. 6, 2025 /PRNewswire/ -- Four clinical trials to be presented at the 67th...

New research re-examines existing practices, identifies gaps and unmet needs ORLANDO, Fla., Dec. 6, 2025 /PRNewswire/ -- Four studies presented at the 67th American Society of Hematology (ASH)...

With an emphasis on real-world data, studies guide application of both longstanding and emerging therapies ORLANDO, Fla., Dec. 6, 2025 /PRNewswire/ -- Five studies presented at the 67th American...

The awards-winning robotics company officially kicks off its pre-order window ahead of its main launch at CES 2026. SINGAPORE, Dec. 5, 2025 /PRNewswire/ -- Strutt, a Singapore-incorporated...